Avidity Biosciences, Inc. — Director's Dealing 2026

Feb 27, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNAM)
CIK: 0001599901
Period of Report: 2026-02-27

Reporting Person: BOESS CARSTEN (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-27	Common Stock	D	6692	—	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-27	Stock Option (Right to Buy)	$33.62	D	10034	Disposed	2035-06-09	Common Stock (10034)	Direct
2026-02-27	Stock Option (Right to Buy)	$39.96	D	13489	Disposed	2034-06-12	Common Stock (13489)	Direct
2026-02-27	Stock Option (Right to Buy)	$12.48	D	22000	Disposed	2033-06-14	Common Stock (22000)	Direct
2026-02-27	Stock Option (Right to Buy)	$12.03	D	22000	Disposed	2032-06-14	Common Stock (22000)	Direct
2026-02-27	Stock Option (Right to Buy)	$26.09	D	15000	Disposed	2031-06-15	Common Stock (15000)	Direct
2026-02-27	Stock Option (Right to Buy)	$8.82	D	20858	Disposed	2030-05-14	Common Stock (20858)	Direct

Footnotes

F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.